Type 2 diabetes is the most common metabolic disorder, affecting Ͼ 5% of the population in Western countries. The pathogenesis of type 2 diabetes is characterized by a combination of peripheral insulin resistance and impaired insulin secretory capacity of pancreatic ␤ cell. Genetic predisposition interacts with environmental factors including diet, physical activity, and age leading to the development of diabetes. Susceptibility to both insulin resistance and insulin deficiency appears to be genetically determined (1). In the majority of the prediabetic population, the earliest abnormality is insulin resistance, which precedes the development of glucose intolerance. Initially, the pancreas attempts to compensate for insulin resistance by increasing insulin production and secretion. When it is unable to maintain sufficient hyperinsulinemic response, overt diabetes ensues. Despite intense investigations, genes responsible for the development of type 2 diabetes remain in dispute.
Type 2 diabetes is the most common metabolic disorder, affecting Ͼ 5% of the population in Western countries. The pathogenesis of type 2 diabetes is characterized by a combination of peripheral insulin resistance and impaired insulin secretory capacity of pancreatic ␤ cell. Genetic predisposition interacts with environmental factors including diet, physical activity, and age leading to the development of diabetes. Susceptibility to both insulin resistance and insulin deficiency appears to be genetically determined (1) . In the majority of the prediabetic population, the earliest abnormality is insulin resistance, which precedes the development of glucose intolerance. Initially, the pancreas attempts to compensate for insulin resistance by increasing insulin production and secretion. When it is unable to maintain sufficient hyperinsulinemic response, overt diabetes ensues. Despite intense investigations, genes responsible for the development of type 2 diabetes remain in dispute.
Insulin initiates a wide variety of growth and metabolic effects by binding to the insulin receptor and activating its intrinsic tyrosine kinase. This event leads to phosphorylation on tyrosine residues of a variety of docking proteins including insulin receptor substrate (IRS) proteins (2) . Phosphorylated IRS proteins serve as multisite docking proteins for various effector molecules possessing src homology 2 (SH2) domains, including phosphatidylinositol 3-kinase (PI 3-kinase) regulatory subunits (p85, p55 p50, p85, and p55 PIK ), the tyrosine kinases Fyn and Csk, the tyrosine protein phosphatase SHP-2/Syp, as well as several smaller adapter molecules such as the growth factor receptor binding proteins Grb-2, Crk, and Nck (3) . Activation of these SH2 domain proteins initiates signaling cascades, leading to the activation of multiple downstream effectors that ultimately transmit the insulin signal to a branching series of intracellular pathways that regulate cell differentiation, growth, survival, and metabolism. Four members of the IRS family have been identified that are considerably similar in their general architecture (4 -7). They are composed of an NH 2 -terminal pleckstrin homology (PH) domain that binds to membrane phospholipids, a phosphotyrosine binding (PTB) domain located just COOH-terminal to the PH domain that is involved in recognition of the asparagine-proline-glutamic acid-phosphotyrosine (NPEpY) sequence located in the juxtamembrane region of the insulin receptor ␤ subunit; and a less conserved COOH-terminal portion with multiple potential tyrosine phosphorylation motifs that can bind to specific SH2 domain-containing proteins. Nevertheless, the four IRS proteins differ in some respects including tissue distribution, developmental expression (8) , subcellular localization (9) , and interaction with SH2 domain-containing proteins (10) . These differences may contribute to specificity in abilities of the IRS proteins to mediate different biological signals. In light of their pivotal role in insulin signaling, the IRS proteins have been considered candidate genes for human metabolic disorders such as type 2 diabetes and obesity.
Here we will focus on recent advances in the understanding of the functional roles of IRS proteins; we will also discuss results of studies in animal models lacking IRS molecules by targeted disruption of the IRS genes. Next, we will review data from human studies of the pathogenetic role of IRS proteins in insulin signaling. Finally, we will discuss the pathogenetic role of IRS amino acid polymorphisms in the development of human metabolic disorders.
IRS-1 STRUCTURE AND FUNCTION
IRS-1 was the first substrate identified and represents the prototype of the IRS family proteins (4) . The human IRS-1 gene is localized on chromosome 2q36 -37 (2) . IRS-1 contains 21 putative tyrosine phosphorylation sites, several of which are located in amino acid sequence motifs that bind to SH-2 domain proteins, including the p85 regulatory subunit of PI 3-kinase, Grb-2, Nck, Crk, Fyn, Csk, phospholipase C␥, and SHP-2 ( Fig. 1) (2) . IRS-1 contains also Ͼ 30 potential serine/threonine phosphorylation sites in motifs recognized by various kinases such as casein kinase II, protein kinase C, protein kinase B/Akt, and mitogen-activated protein (MAP) kinases (2, 4) . The relevance of IRS-1 in insulin/IGF-I signaling was first suggested by in vitro studies in which IRS-1 was overexpressed or its levels were decreased by antisense mRNA. Subsequently, it was shown that overexpression of IRS-1 in CHO cells or 32D cells, a myeloid progenitor cell line lacking both IRS-1 and IRS-2, enhanced mitogenetic effects of insulin (11) (12) (13) . Expression in isolated rat adipocytes of an antisense ribozyme directed against rat IRS-1 resulted in a fourfold decrease in the sensitivity of the doseresponse curve for insulin-stimulated translocation of glucose transporter GLUT4 to the cell surface (14) . Overexpression of recombinant human IRS-1 in L6 rat myocytes induced an increase in insulin sensitivity and responsiveness for glucose transport, translocation of GLUT1 and GLUT4, and glycogen synthesis (15) .
The importance of IRS-1 in insulin/IGF-I signaling was further confirmed in studies with cells or tissues isolated from knockout mice lacking IRS-1 (16, 17) . Primary adipocytes from knockout mice lacking IRS-1 showed a decrease in glucose transport and GLUT4 translocation to the plasma membrane in response to insulin (17) . In agreement with these results, it has been shown in human adipocytes that IRS-1 is the main docking protein for the binding and activation of PI 3-kinase in response to insulin (18) . Moreover, it has recently been reported that differentiation of human preadipocytes to mature adipocytes was characterized by a marked (Ͼ10-fold) increase in IRS-1 protein expression whereas IRS-2 expression was modestly increased (Ͼ2-fold) (19) . These changes were associated with full development of the human adipocyte phenotype, including increased insulin-stimulated glucose transport capacity and increased expression of GLUT4 (19) . Fibroblasts derived from knockout mice lacking IRS-1 displayed an impaired rate of proliferation in response to IGF-I (20) , whereas the lack of IRS-1 in brown adipocytes derived from the same animals resulted in both impairment in differentiation and a reduction in lipid synthesis in response to insulin (21, 22) . More recent studies have shown that IRS-1 may play also an important role in regulating insulin secretion in pancreatic ␤ cells. Overexpression of IRS-1 in ␤TC6-F7 or RIN 1046 -38 insulinoma cell lines resulted in an increased secretory response to glucose and glibenclamide, a second-generation sulfonylurea (23, 24) . Islets from knockout mice lacking IRS-1 exhibited marked defects in insulin content and the insulin secretory response to glucose (25) . Taken together, these data indicate that IRS-1 plays a key role in mediating both metabolic and mitogenic effects of insulin in peripheral tissues such as muscle and adipose tissue, and suggest a novel important role for IRS-1 in ␤ cell function.
IRS-2 STRUCTURE AND FUNCTION
IRS-2 was initially identified as an alternative substrate for the insulin receptor in animals with targeted disruption of the IRS-1 gene (16, 17) . The cloned IRS-2 cDNA revealed a predicted protein that is 100 residues longer than IRS-1 but sharing many structural and functional characteristics with IRS-1 ( Fig. 1) (5) . The human IRS-2 gene is localized on chromosome 13q34 (26) . Human IRS-2 contains 22 potential tyrosine phosphorylation sites, but only 13 are conserved in IRS-1. The amino acid sequence identity between IRS-1 and IRS-2 is 43%, with some domains such as the PH and PTB domains exhibiting higher degrees of identity (65 and 75%, respectively). The COOH-terminal domains of IRS-1 and IRS-2 are poorly conserved, displaying only 35% identity, which arises largely from similar tyrosine phosphorylation motifs surrounded by variable stretches of amino acid sequence. The middle of IRS-2 possesses a unique region comprising amino acids 591-786 that interacts specifically with the kinase regulatory loop binding (KRLB) domain of the insulin receptor ␤ subunit (11) . Because this region is absent in IRS-1, this domain may contribute to the signaling specificity of IRS-2. In addition, IRS-1 and IRS-2 may regulate unique signaling pathways because of different tissue distribution, subcellular localization, kinetics of activation/ deactivation, or specificity of interaction with downstream effectors (8, 10, 27) . For example, it has been shown that IRS-1 and IRS-2 differ in their subcellular localization since IRS-1 is twofold more concentrated in the intracellular membrane compartment than in cytosol, whereas IRS-2 is twofold more concentrated in cytosol than in the intracellular membrane compartment (28) . Further studies have shown that IRS-2 is dephosphorylated more rapidly and activates PI 3-kinase more transiently than IRS-1, thus indicating that differences in kinetics of activation may contribute to the diversity of the insulin signaling transduced by IRS-1 and IRS-2 (28, 29). Finally, IRS-1 and IRS-2 exhibit differences in their capacity to interact with various downstream signaling elements containing the SH2 domain (2, 10). Thus, in vitro studies have shown that IRS-1 and IRS-2 both bind PI 3-kinase, Grb-2, Crk, Fyn, and phospholipase C␥, whereas only IRS-1 binds Abl and SHP-2 (2, 10) . In vivo studies with knockout animal models have revealed several differences in the signaling capacity of IRS-1 and IRS-2, as will be discussed later in detail.
IRS-3 STRUCTURE AND FUNCTION
IRS-3 was initially detected in rat adipocytes (30) as a tyrosine-phosphorylated substrate of the insulin receptor. Cloning of rat (6) and mouse (31) IRS-3 (rIRS-3 and mIRS3) revealed proteins 700 -800 amino acid residues shorter than IRS-1 and IRS-2, but possessing a similar architecture comprising a PH domain, a PTB domain, and a COOH-terminal domain. The mouse IRS-3 gene is localized on the telomeric region of the chromosome 5G2 (31) . The PH domain in rIRS-3 is homologous to the PH domain in IRS-1 and IRS-2 (50% and 45% sequence identity with rat IRS-1 and IRS-2, respectively). The PTB domain in rIRS-3 exhibits 48% and 53% sequence identity with the corresponding domains in IRS-1 and IRS-2, respectively. Outside of the PH and PTB domains, there is no extended homology between IRS-3 and either IRS-1 or IRS-2. In the carboxyl-terminal domain of IRS-3, 13 tyrosine residues are potential sites of tyrosine phosphorylation ( Table  1 ) (6) . Subsequent studies have shown that IRS-3 binds PI 3-kinase, SHP-2, Nck, and Shc, but Grb-2 and phospholipase C␥ only weakly (32) . In addition to adipose tissue where IRS-3 was originally isolated, IRS-3 mRNA is expressed in other tissues including liver, lung, kidney, ovary, heart, fibroblasts, and ␤TC-1 and ␤TC-7 insulinoma cells (8, 31) . At a subcellular level, IRS-3 is located mainly in the plasma membrane, where it activates PI 3-kinase in response to insulin (9) . However, IRS-3 does not seem to be expressed in human cells, so its relevance in human metabolic disorders is questionable.
In adipocytes isolated from knockout mice lacking IRS-1, ϳ50% of insulin-stimulated glucose transport and GLUT4 translocation was preserved by a signaling pathway involving IRS-3 rather than IRS-2 (33). Furthermore, overexpression of IRS-3 in isolated rat adipocytes results in a supramaximal increase in the number of GLUT4 molecules translocated to the cell surface even in the absence of insulin (34) . In rat liver-derived HTC cells, IRS-3 showed robust and prolonged tyrosine phosphorylation upon insulin stimulation resulting in sustained association with the p85 regulatory subunit of PI 3-kinase (35) . It has also been shown that upon insulin stimulation, the p85 subunit of PI 3-kinase associated with IRS-3 more rapidly than with IRS-1 and IRS-2 in rat adipocytes (36) . The functional significance of differences in the time course between IRS-3 and IRS-1/2 is not clear. Notably, overexpression of IRS-3 in 3T3 embryonic fibroblasts derived from knockout mice lacking IRS-1 resulted in increased DNA synthesis stimulated by IGF-I despite the drastic impairment of IRS-1-and IRS-2-mediated signaling (37) . Thus, in addition to metabolic signals, IRS-3 seems to be able to mediate mitogenic signals.
IRS-4 STRUCTURE AND FUNCTION
IRS-4 is the last member of the IRS family to be identified; it was initially detected as a 160-kDa protein in human embryonic kidney (HEK) 293 cell line that was rapidly tyrosine-phosphorylated in response to insulin but was immunologically distinct from IRS-1 (38) . Cloning of human IRS-4 has revealed a 1257 amino acid protein that possesses the typical architecture of the other three members of the IRS family consisting of a PH domain, a PTB domain, and a COOH-terminal domain ( Fig. 1 ) (7). The human IRS-4 gene is localized on the X chromosome. Overall, IRS-4 displays only 27% and 29% sequence identity with IRS-1 and IRS-2, respectively. However, PH and PTB domains of IRS-4 exhibit a higher degree of homology with the corresponding IRS-1, IRS-2, and IRS-3 domains. IRS-4 contains 12 potential tyrosine phosphorylation sites, 7 of which lie within the YXXM motif that binds the SH2 domain of the p85 regulatory subunit of PI 3-kinase. One potential tyrosine phosphorylation site lies in a motif that is expected to bind the SH2 domain of Grb-2, and another site in the motifs known to bind the NH 2 -terminal domain of either SHP-2 or phospholipase C␥. In vitro studies with HEK cells confirmed that IRS-4 binds PI 3-kinase and Grb-2, but not SHP-2 or phospholipase C␥ (38) . Analysis of IRS-4 mRNA distribution by a highly sensitive RT-PCR method revealed that expression of IRS-4 mRNA is very low but is not limited to human embryonic kidney 293 cells, where it was originally identified (8, 39, 40) . Indeed, IRS-4 is expressed in various human tissues and cell lines including pituitary, thyroid, ovary, prostate, fibroblasts, IM-9 lymphoblastoid cells, U-2 OS osteogenic sarcoma, Hep-2 larynx carcinoma cells, A-431 epidermoid carcinoma cells, and several murine tissues including skeletal muscle, brain, hypothalamus, liver, heart, kidney, ␤TC-1 and ␤TC-7 insulinoma cell lines, but not in the spleen or lung (8, 39, 40) . It has been shown that differentiation of L6 rat myoblast cells or P19 pluripotent embryonal carcinoma cells into myotubes was characterized by a marked increase in IRS-4 mRNA expression, whereas expression of the other IRS members did not change, thus raising the possibility that IRS-4 may regulate unique signaling pathways involved in mechanisms of cell differentiation (8) . However, IRS-4 is a nonabundant protein since it cannot be detected in any tissue by standard immunological methods (39) . At the subcellular level, IRS-4 appears to be localized at the plasma membrane (38) .
The functional role of IRS-4 was investigated by in vitro experiments. Overexpression of IRS-4 in rat adipocytes led to a marked increase in the number of GLUT4 molecules recruited to the cell surface (34) , whereas overexpression of IRS-4 in 32D hematopoietic cells lacking any IRS proteins or in NIH-3T3 mouse fibroblasts resulted in an increased capability of insulin and IGF-I to stimulate cell proliferation (41, 42) . However, in contrast to IRS-1 and IRS-2, IRS-4 overexpression in 32D cells failed to promote cell survival, indicating that IRS-4 has different signaling capacity compared with IRS-1 and IRS-2 (40). More recently, it has been shown that IRS-3 and IRS-4 may act as negative regulators of IGF-I signaling by suppressing the function of IRS-1 and IRS-2 at several steps (37) . Thus, overexpression of both IRS-3 and IRS-4 caused a decrease in IRS-2 mRNA and protein. IRS-3 overexpression also induced a reduction in IGF-I-stimulated tyrosine phosphorylation of IRS-1, whereas IRS-4 overexpression decreased the phosphorylation of both IRS-1 and IRS-2. Finally, overexpression of both IRS-3 and IRS-4 caused a decrease in association of IRS-1 and IRS-2 with the p85 regulatory subunit of PI 3-kinase (37) . Therefore, the biological responses to IGF-I in certain tissues may be modulated by a combination of all four IRS proteins.
KNOCKOUT MOUSE MODELS LACKING IRSs
Gene knockout technology has been used widely to investigate the physiological roles of the IRS family proteins. Knockout mice lacking IRS-1 (IRS-1 Ϫ/Ϫ ) were born alive but exhibited retardation in embryonal and postnatal growth (16, 17) , indicating that IRS-1 is important for growth-promoting effects of IGF-I. However, analysis of organ weights indicates organ-specific differences in the role of IRS-1 as a mediator of growth-promoting effects of IGF-I (43). Thus, skeletal muscle and liver growth required IRS-1 whereas growth of brain, small intestine, and spleen did not. Other organs such as kidney and heart showed sexual dimorphism, since their growth was affected more in females than in males (43) . IRS-1 Ϫ/Ϫ mice also showed resistance to the glucose-lowering effects of insulin and IGF-I, but had normal fasting glycemia and a mild glucose intolerance from compensatory hyperinsulin-emia caused by selective ␤ cell hyperplasia. However, even though ␤ cell mass was increased in IRS-1 Ϫ/Ϫ mice, islets from these animals exhibited defects in insulin content and secretion in response to glucose (25, 44) . These defects are caused by impairment in the autocrine-activated release of Ca 2ϩ from intracellular Ca 2ϩ stores, resulting in a decrease in intracellular free Ca 2ϩ concentration (45) . Hyperinsulinemic-euglycemic clamp studies have clarified the relative contribution of the key insulin-responsive organs (skeletal muscle, liver, and adipose tissue) to in vivo insulin resistance. IRS-1 Ϫ/Ϫ mice showed a marked defect in insulin-stimulated glucose transport and muscle glycogen synthesis (46, 47) . At the molecular level, this defect is caused by reduced insulin-stimulated PI 3-kinase activity associated with tyrosine-phosphorylated proteins in skeletal muscle, which are not compensated by a constitutive increase in the IRS-2 protein content and, upon insulin stimulation, in its activation (46, 47) . By contrast, insulin-mediated suppression of hepatic glucose production was relatively unaffected because of full compensation by IRS-2, resulting in insulin-stimulated PI 3-kinase activity associated with tyrosine-phosphorylated proteins equivalent to that of wild-type mice (46, 47) . It has been also shown that IRS-1 Ϫ/Ϫ mice exhibited features of syndrome X, including hypertriglyceridemia, hypertension, and impaired endothelium-dependent vascular relaxation (48) . The former effect may be caused by both reduced lipoprotein lipase activity and diminished lipid synthesis in the adipose tissue (21) . More recently, it has been reported that IRS-1 Ϫ/Ϫ mice showed severe osteopenia with low bone turnover, a characteristic of senile osteoporosis in aged humans (49) . Osteoblasts from IRS-1 Ϫ/Ϫ mice showed defects in proliferation and differentiation induced by IGF-I and insulin, as well as impairment in the ability to support osteoclastogenesis. Thus, IRS-1 may play a critical role in maintaining bone turnover by mediating anabolic actions of insulin and IGF-I.
Unlike IRS-1 Ϫ/Ϫ mice, knockout mice lacking IRS-2 (IRS-2 Ϫ/Ϫ ) exhibit nearly normal birth size and body weight, but show insulin resistance with abnormal glucose tolerance at birth and progressively develop fasting hyperglycemia as a result of inadequate compensatory insulin secretion because of reduced ␤ cell mass (44, 50) . This event appears to be caused by defects in ␤ cell development and increased ␤ cell apoptosis due to the failure of IGF-I to promote these effects through IRS-2 signaling (51). Even though ␤ cell mass was reduced in IRS-2 Ϫ/Ϫ mice, individual ␤ cell showed normal or increased insulin secretion in response to glucose (44) . Using a hyperinsulinemic-euglycemic clamp technique, it has been demonstrated that IRS-2 Ϫ/Ϫ mice were characterized by a defect in muscle glycogen synthesis, a marked decrease in the ability of insulin to suppress hepatic glucose production, and a reduced hepatic glycogen synthesis (46) . IRS-2 Ϫ/Ϫ mice also exhibited marked insulin resistance in adipose tissue as reflected by decreased suppression of plasma free fatty acid levels and glycerol turnover during the hyperinsulinemic-euglycemic clamp (46) . Skeletal muscle obtained from IRS-2 Ϫ/Ϫ mice showed normal basal and insulin-stimulated glucose uptake when isolated from animals with near-normal blood glucose levels (52) . By contrast, skeletal muscle isolated from IRS-2 Ϫ/Ϫ mice that had developed severe hyperglycemia exhibited impaired basal and insulin-stimulated glucose uptake, suggesting that prolonged hyperglycemia due to hepatic insulin resistance and ␤ cell failure, rather than the lack of IRS-2 in skeletal muscle, was the principal mechanism for in vivo insulin resistance (44, 50, 52) . At a molecular level, insulin-stimulated PI 3-kinase activity associated with tyrosine-phosphorylated proteins was reduced in the liver of IRS-2 Ϫ/Ϫ mice but normal in their skeletal muscle (44) . Accordingly, previous studies with IRS-1 knockout mice or cells derived from these mice have suggested that IRS-2 could compensate for IRS-1 deficiency more effectively in liver and pancreatic ␤ cells than in skeletal muscle, fibroblasts, or adipocytes (16, 17, 20, 33, 47) . Studies in mice with combined heterozygous knockout of the insulin receptors IRS-1 and IRS-2 suggest that IRS-1 plays a prominent role in skeletal muscle as does IRS-2 in the liver (53) .
More recently, it has been shown that IRS-2
females exhibited defects in the hypothalamic-pituitaryovarian axis resulting in infertility and moderate obesity (54) . Ovaries from IRS-2 Ϫ/Ϫ mice were small and showed features of anovulatory including decreased number of follicles, thickening of the cortex and of the stroma, and an almost complete absence of corpora lutea (54) . Plasma concentrations of luteinizing hormone, prolactin and sex steroids were reduced in IRS-2 Ϫ/Ϫ mice, and these animals were also resistant to exogenous gonadotropin stimulation. Pituitaries were reduced in size and contained diminished numbers of gonadotrophs, but not of somatotrophs. IRS-2 Ϫ/Ϫ females also showed increased food intake, moderate obesity, and increased body fat despite elevated leptin levels. These results raise the intriguing possibility that dysregulation of IRS-2 expression or function may represent one of the molecular defects responsible for human infertility associated with insulin-resistant conditions such as polycystic ovarian syndrome, and will be discussed below.
Taken together, these data suggest that IRS-1 and IRS-2 are not functionally interchangeable in tissues that are responsible for glucose production (liver), glucose uptake (skeletal muscle and adipose tissue), and insulin production (pancreatic ␤ cells). Thus, IRS-2 seems to have a major role in regulating hepatic insulin action and in controlling pancreatic ␤ cell development and survival. By contrast, in tissues such as skeletal muscle and adipose tissue, defects in IRS-1 signaling cannot be entirely compensated for by IRS-2 (Fig. 2) .
Knockout mice lacking IRS-3 exhibited normal growth throughout development, normal glucose and insulin levels in the fed and fasted state, normal glucose tolerance, as well as normal basal and insulin-stimu-lated glucose transport in isolated adipocytes, thus arguing against a major role of this substrate in mediating biological signals of insulin (55) .
Knockout mice lacking IRS-4 exhibited slightly reduced weight, slightly lower glucose levels associated with normal plasma insulin levels, and a slightly impaired oral glucose tolerance test but a normal intraperitoneal insulin tolerance test (56) . Female mice lacking IRS-4 were less fertile than the wild-type. Because IRS-4 is expressed in organs important for reproduction such as hypothalamus, pituitary, and ovary, it is tempting to speculate that IRS-4 may be involved in controlling fertility. Overall, the results of in vivo studies are not supportive of a major physiological role for IRS-4 in controlling both growth and glucose metabolism.
IRS EXPRESSION AND FUNCTION IN HUMANS
Defects in IRS expression and function have been reported in target tissues of insulin action from insulinresistant subjects. In skeletal muscle strips from morbidly obese subjects, it was observed a significant reduction in IRS-1 content, insulin-stimulated IRS-1 phosphorylation, and PI 3-kinase activation that was paralleled by a decrease in insulin-stimulated glucose uptake (57) . A decrease in insulin-stimulated IRS-1 phosphorylation and PI 3-kinase activity, but not IRS-1 content, was also observed in skeletal muscle obtained from nonobese type 2 diabetic patients during a modified hyperinsulinemic clamp (58) . Accordingly, in skeletal muscle biopsies obtained from obese type 2 diabetic patients before and at the end of a 3 h hyperinsulinemic-euglycemic clamp, a decrease in both IRS-1-and IRS-2-associated PI 3-kinase activity was observed (59) . Impairment in insulin-stimulated phosphorylation of IRS-1 has been described in skeletal muscle from pregnant obese women with and without gestational diabetes (60). This defect was primarily due to decreased expression of IRS-1 protein, whereas IRS-2 expression appeared to be increased and correlated significantly with impairment in glucose transport (60) . A similar shift from IRS-1 to IRS-2 expression has been observed in ovaries from women with gestational diabetes and polycystic ovary syndrome (61) . In women with normal ovulation, IRS-1 was the main insulin substrate with wide distribution in all compartments of the follicle including the oocyte, granulosa, thecal cells, and stromal cells. By contrast, IRS-2 expression is restricted to the theca interna. Furthermore, expression of IRS-1 increased during follicular development whereas IRS-2 remained unchanged. In women with gestational diabetes or polycystic ovary syndrome, expression of IRS-2 increased in oocytes, granulosa cells, and theca internal cells whereas IRS-1 expression decreased in the granulosa cells (61) . Because IRS-2 was shown to be an antiapoptotic mediator (62), overexpression of IRS-2 in antral follicles may affect their physiological apoptosis resulting in later accumulation of larger cysts, a typical feature of polycystic ovary syndrome. A reduction in IRS-1 expression has been also reported in isolated adipocytes from type 2 diabetic patients (18) . In these cells, IRS-2 levels remained unchanged but did not fully compensate for IRS-1 down-regulation (18) . Low IRS-1 gene and protein expression in adipocytes has been described in 30% of subjects at high risk for type 2 diabetes, i.e., first-degree relatives of type 2 diabetics and morbidly obese subjects (63) . Moreover, subjects with low IRS-1 expression were characterized by clinical features of the insulin resistance syndrome including higher fasting glucose and insulin levels, higher triglyceride levels, and higher visceral adiposity measured by waist/hip ratio (63) . Overall, these results indicate that low expression of IRS-1 in target tissues of insulin action (i.e., skeletal muscle and adipose tissue) may be considered a molecular marker of insulin-resistant states such as obesity and type 2 diabetes. 
IRS POLYMORPHISMS IN TYPE 2 DIABETES IRS-1 polymorphisms in type 2 diabetes
Molecular scanning of the IRS-1 gene in more than 4,000 normal individuals and patients with type 2 diabetes from different ethnic groups has revealed several polymorphisms resulting in amino acid substitutions ( Table 2 ) (64 -78) . Overall, the frequency of IRS-1 polymorphisms is higher in type 2 diabetic patients than in control subjects. Of these, the Gly3 Arg change at codon 972 (Arg 972 ) IRS-1) is the most common, and has been studied most extensively (64 -78) . Several reports have indicated a higher prevalence of the Arg 972 polymorphism in type 2 diabetic patients (64 -68) , although other studies have reported a weak (69 -73) or absent (74 -58) association between this variant and type 2 diabetes. Possible explanations for these divergent results may lie in the ethnic differences in the genetic background for type 2 diabetes. For example, the prevalence of the Arg 972 polymorphism in both diabetic and control Japanese populations appears to be lower than that observed in the corresponding Caucasian populations (3.8 vs. 10.6% in type 2 diabetes, and 4.0% vs. 6.5% in control subjects, respectively). In Japanese populations, however, insulin sensitivity (measured by hyperinsulinemic-euglycemic clamp) is decreased by 22% in normal and by 29.5% in type 2 diabetic subjects with the Arg 972 polymorphism vs. those in comparable groups without polymorphism (71) . Curiously, the Arg 972 polymorphism is absent in Pima Indians (78) .
Besides ethnic differences, significant regional differences in the prevalence of the Arg 972 polymorphism have been observed between Dutch nondiabetic subjects from Hoorn and Rotterdam (9.4 vs. 18.6%; PϽ0.05) (76) , thus complicating the interpretation of association study of this IRS-1 variant. Another possible explanation may lie in the number of subjects examined in a single study. Using exact permutational methods, the number of subjects needed to achieve a conventional level of significance, assuming the Arg 972 polymorphism is present in 10% of type 2 diabetic patients and 5% of control subjects, has been estimated (66) . To detect an association with a P value of 0.01, 380 diabetic and 380 control subjects would need to be analyzed. Therefore, most published studies by themselves lack the power to determine an association between the Arg 972 variant and type 2 diabetes. By contrast, when all available studies in Caucasian populations are pooled, an overall association between type 2 diabetes and the Arg 972 polymorphism ensues (66, 68) .
Finally, because type 2 diabetes is a heterogeneous disorder, the Arg 972 IRS-1 polymorphism may act in combination with environmental factor such as diet, physical activity, and age to confer susceptibility to diabetes. Consistent with this idea, the Arg 972 polymorphism of IRS-1 in its heterozygous form is associated in obese nondiabetic subjects with a 50% reduction in insulin sensitivity vs. obese subjects without polymorphism, indicating that the polymorphism potentiates obesity-linked insulin resistance (79) . These obese carriers of the Arg 972 IRS-1 polymorphism are also characterized by a clustering of metabolic cardiovascular risk factors with elevated fasting levels of plasma glucose, serum triglyceride, plasma tissue-plasminogen-activator, and its inhibitor PAI-1, which suggests that the polymorphism potentiate obesity-linked insulin resistance (79) . In a group of subjects selected from the UK Prospective Diabetes Study (UKPDS), the prevalence Arg 972 IRS-1 polymorphism was increased in subjects with type 2 diabetes who had insulin resistance associated or not with dyslipidemia (67) . More recently, a 2.8-fold higher frequency of the Arg 972 IRS-1 polymorphism has been reported in patients with angiographic evidence of coronary artery disease (CAD) than in control individuals (80) . When adjusted for other risk factors, the relative risk of CAD associated with the Arg 972 IRS-1 polymorphism was 2.93-fold higher than in wild-type individuals, and it increased to 6.97-fold in obese subjects and to 27.3-fold in subjects with clinical features of insulin resistance syndrome (80) . The Arg 972 IRS-1 polymorphism was also associated with a higher frequency of diabetes, hypertriglyceridemia, and hypercholesterolemia (80) . However, these results have not been confirmed in another study of 169 overweight/obese patients with type 2 diabetes (73) . Possible explanations for these apparent contradictions Lys 3 Thr may lie in ethnic differences, different degree of insulin resistance, interaction with other metabolic factor, size of examined population sample. The Arg 972 IRS-1 variant was not associated with decreased birth weight, which has been proposed as a risk factor for insulin resistance and type 2 diabetes (81). Diabetic patients with the Arg 972 IRS-1 variant are further characterized by lower plasma levels of fasting insulin and C-peptide (64) . In addition, glucose-tolerant subjects who were heterozygous for the Arg 972 variant exhibited a lower insulin response to an oral glucose load and decreased insulin secretion during a hyperglycemic clamp compared with noncarriers (82) . Taken together, these observations raise the possibility that the Arg 972 IRS-1 polymorphism in combination with both defects in other candidate genes and environmental factors may account for the phenotype of peripheral insulin resistance and impaired insulin secretion, the two typical features of type 2 diabetes.
A series of in vitro studies has been carried out to investigate the functional effects of the Gly3 Arg change at codon 972 on insulin action and insulin secretion (15, 24, (83) (84) (85) . Expression of the Arg IRS-1 variant interfered with the interaction between IRS-1 and the SH2 domains of PI 3-kinase, possibly by altering the tertiary structure of IRS-1. The net effect was a 32% decrease in the mitogenic effects of insulin (83, 84) . More recent studies have addressed the question of the functional significance of the Arg 972 IRS-1 variant on insulin-dependent glucose metabolism (15) . Expression of the Arg 972 IRS-1 variant in L6 skeletal muscle cells resulted in a decrease in both basal and insulin-stimulated glucose transport compared with L6 cells expressing wild-type IRS-1 (15) . These alterations were associated with a reduction in the amount of GLUT4 translocated to the plasma membrane under both the basal condition and in response to insulin, without changes in total cellular GLUT4 protein content. The molecular mechanism by which the Arg 972 IRS-1 variant affected glucose metabolism was further elucidated by experiments examining downstream targets in PI 3-kinase signaling pathway. There is evidence that the Ser/Thr kinase Akt, a downstream effector of PI 3-kinase, acts as a key enzyme linking PI 3-kinase activation to multiple biological function of insulin, including glucose transport and glucose transporters translocation to the plasma membrane (86) . Consistent with this idea, expression of the Arg 972 IRS-1 variant in L6 myocytes resulted in a significant decrease in Akt phosphorylation and activity because of defective IRS-1-associated PI 3-kinase (15) . Akt has been also implicated in the regulation of glycogen synthesis through a mechanism involving phosphorylation and inactivation of glycogen synthase kinase 3 (GSK-3) that results in increased activity of the active dephosphorylated form of glycogen synthase. Expression of the Arg 972 IRS-1 variant in L6 myocytes resulted in a significant decrease in GSK-3 phosphorylation and inactivation by Akt; these defects are associated with a reduction in insulinstimulated glucose incorporation into glycogen and glycogen synthase activity (15) . Overall, these results suggest that the Arg 972 IRS-1 polymorphism might contribute to the development of insulin resistance by impairing the ability of insulin to activate the IRS-1/PI 3-kinase/Akt/GSK-3 signaling pathway, thus leading to defects in glucose transport, glucose transporters translocation and glycogen synthesis.
As reported above, diabetic and prediabetic carriers of the Arg 972 IRS-1 variant are characterized by a low fasting plasma concentration of insulin and C-peptide (64, 82) . There is increasing evidence that insulin synthesis and secretion may be modulated by autocrine activation of the insulin signaling involving insulin receptor phosphorylation, tyrosine phosphorylation of IRS-1, and activation of PI 3-kinase (23) (24) (25) . These observations have led us to hypothesize that the Arg 972 IRS-1 polymorphism may affect pancreatic ␤ cell insulin secretion. Expression of the Arg 972 variant in RIN rat ␤ cell line resulted in a 60% decrease in binding of the p85 subunit of PI 3-kinase to IRS-1 and a 50% decrease in IRS-1-associated PI 3-kinase activity, whereas expression or function of endogenous IRS-2 was not affected (24) . These changes caused a marked decrease in insulin secretory response to glucose and glibenclamide (24) (Fig. 3) . A more recent study has addressed the role of Arg 972 IRS-1 variant in human pancreatic islet function and survival (87) . The results obtained document that pancreatic islets isolated from carriers of Arg 972 IRS-1 exhibited impaired IRS-1-associated PI 3-kinase activity, reduced insulin secretion, and increased apoptosis and were resistant to the antiapoptotic effect of insulin compared with wild-type controls. The same results were reproduced in the RIN rat ␤ cell line stably expressing either wild-type IRS-1 or Arg 972 IRS-1 variant. A defective activation of the PI 3-kinase/Akt survival pathway resulting in lower phosphorylation and inactivation of the proapoptotic protein Bad, a member of the Bcl-2 family of proteins known to play a central role in the regulation of cell death, appeared to be the mechanism responsible for the increased apoptosis observed in pancreatic islets isolated from carriers of Arg 972 IRS-1 (87). Several additional polymorphisms resulting in amino acid substitutions have been described, but their frequency is lower than that of the Arg 972 IRS-1 variant ( Table 2 (71) . Two of these, Arg 170 and Thr 209 , are located in the PTB domain of IRS-1, and the nonconservative substitutions of the native residues were expected to affect the interaction of IRS-1 with the insulin receptor. Consistent with this hypothesis, expression of the Arg 170 and the Thr 209 IRS-1 variant in 32D-IR cells both resulted in a reduced binding to the insulin receptor on insulin stimulation leading to a decrease in tyrosine phosphorylation of IRS-1, PI 3-kinase activation, MAP kinase activity, and DNA synthesis (84) . Although the functional significance of the Ser3 Phe 809 IRS-1 variant has not been studied in vitro, this polymorphism has been detected only in type 2 diabetic subjects (71) . In addition, diabetic carriers of the Phe 809 IRS-1 variant exhibited higher HBA1c, fasting glucose, and postprandial glucose levels than diabetic noncarrier (50) . Phenotype analysis of type 2 diabetic patients who are heterozygous for the Pro 513 IRS-1 polymorphism did not reveal any significant differences compared with wild-type diabetic subjects, which argues against a major pathogenetic role of this IRS-1 variant (64, 67).
IRS-2 polymorphisms in type 2 diabetes
In contrast to the phenotype of IRS-2 Ϫ/Ϫ mice, polymorphisms of the human IRS-2 gene did not appear to contribute to the pathogenesis of either the common form of type 2 diabetes or early-onset autosomal dominant type 2 diabetes (Table 1) (26, 88 -91) . No genetic variability has been identified in the promoter sequence of IRS-2 in type 2 diabetic patients, which suggests that mutations causing alterations in IRS-2 expression levels are rare (89) . A relatively common IRS-2 polymorphism causing the Gly3 Asp change at codon 1057 has been detected in a Danish population. However, its allelic frequency was similar in both normal subjects (33.9%) and type 2 diabetic patients (33.8%) (88) . A much less frequent IRS-2 polymorphism that causes the Gly3 Ser change at codon 879 has been also detected in the same population and shows no differences in frequency between normal and diabetic subjects (88) .
The potential effect of the Asp 1057 IRS-2 variant on insulin secretion and insulin sensitivity has been examined in four groups of glucose-tolerant Scandinavian subjects (89) . This polymorphism had no detectable effect on insulin secretion and insulin sensitivity in a group of 363 young healthy Danish subjects, in a group of 228 Danish glucose-tolerant offspring of one type 2 diabetic parent or in a cohort of 639 glucose-tolerant elderly Swedish men. In contrast, examination of 236 middle-aged glucose-tolerant Danish subjects showed that homozygous carriers of the Asp 1057 IRS-2 variant were characterized by a 25% decrease in fasting insulin levels and a 17% decrease in fasting C-peptide levels compared with wild-type carriers (89) . The serum insulin and C-peptide concentrations of the homozygous carriers of the Asp 1057 IRS-2 variant remained decreased during an oral glucose tolerance test. Despite the reductions in serum insulin and C-peptide concentrations, plasma glucose levels were not altered in homozygous carriers of the Asp 1057 IRS-2 variant vs. wild-type carriers (89) .
The lack of an overall association between the Asp 1057 IRS-2 variant and type 2 diabetes has been also reported in an Italian population (91) (92) . Thus, these data indicate that polymorphisms in IRS-4 are common in Caucasian populations but are not associated with type 2 diabetes or insulin resistance, consistent with the failure of IRS-4 knockout mice to result in a diabetic phenotype (92) .
CONCLUSIONS
The role of IRS proteins as key mediators of insulin signaling is well established. It is less clear whether the four members of the IRS family play redundant or specific roles in insulin signal transduction. Although the IRS molecules are phylogenetically conserved and share structural similarities, there are differences in phosphorylation motifs, tissue distribution, subcellular localization, developmental expression, binding to the insulin receptor, and interaction with SH2 domaincontaining proteins. These differences may provide a potential mechanism for signaling diversity by the four molecules through the formation of specific signaling complexes in different intracellular sites of different tissues.
The search for specific genetic defects that contribute to the main defects in type 2 diabetes, i.e., insulin resistance and insulin deficiency, is complicated by the fact that this syndrome is polygenic with complex inheritance patterns. Although considerable effort has been devoted to identifying potential disease-causing mutations in candidate genes, no single major susceptibility gene for the common form of type 2 diabetes has been identified. The most likely explanation for these disappointing results is that type 2 diabetes consists of several subtypes of the disease, where a combination of different mechanisms (including genetic and environmental factors) acts synergistically to impair insulin secretion and action. Thus, the modest association between the Arg 972 polymorphism of IRS-1 and type 2 diabetes suggests that this relatively common mutation may contribute to the pathogenesis of type 2 diabetes in a small subgroup of cases. Furthermore, it is possible that the Arg 972 IRS-1 variant is not a sufficient cause of diabetes, but interacts with environmental factors to impair insulin sensitivity. In addition, a combination of two or more mild genetic defects in insulin signaling may account for the multifactorial nature of the disease, as demonstrated in transgenic mice with simultaneous disruption of two distinct genes such as IRS-1 and insulin receptor (93) or IRS-1 and glucokinase (94) . As the molecular mechanisms regulating insulin secretion and insulin action unfold, we will have increasing possibilities to elucidate the role of specific insulin signaling elements in insulin action and ␤ cell function and to design efficacious, safe, and convenient interventions. The study of animals with targeted disruption of genes encoding the four IRS proteins has provided important clues to the pathophysiological role of these signaling molecules. 
